However, few clinically relevant points can be drawn from this case: (i) patients with severe obstructive HCM and hypertension should be given special attention during mavacamten titration; (ii) these patients should self-monitor the BP during this phase; and (iii) ideally, baseline hypertension should be treated and controlled the best way possible before initiation of myosin inhibitor treatment. This evidence concerns the gene MYH14 and hypertensive disorder.